-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue

The Motley Fool·11/17/2026 18:50:02
Listen to the news

Key Points

  • Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period.

  • Over roughly the last eight quarters, Johnson & Johnson achieved steady quarter-over-quarter revenue growth, while Pfizer experienced a volatile quarter-over-quarter trajectory marked by repeating fluctuations.

  • Investors should closely monitor whether the revenue gap between the two companies continues to widen in upcoming quarters or eventually begins to narrow.

Johnson & Johnson: Steady Upward Recent Revenue Growth

Johnson & Johnson (NYSE:JNJ) primarily generates revenue by developing and selling pharmaceutical and medical technology products globally.

It recently entered a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, and it received U.S. Food and Drug Administration approval for a new targeted cancer therapy.

Pfizer: Uneven and Volatile Recent Revenue Patterns

Pfizer (NYSE:PFE) primarily generates revenue by developing, manufacturing, and commercializing prescription medicines and vaccines for individuals worldwide.

It recently announced a $1.5 billion funding agreement with Blackstone Life Sciences, and it secured expanded regulatory approval from the U.S. Food and Drug Administration for a cancer treatment regimen.

Why Revenue Matters for Investors

Revenue here refers to the data provider's standardized income-statement revenue line item, and it shows the total money a business brings in from sales before deducting any operating costs.

Johnson & Johnson vs. Pfizer Revenue chart

Johnson & Johnson vs. Pfizer Revenue over the last 8 quarters.

Quarterly Revenue for Johnson & Johnson and Pfizer

Calendar quarter Johnson & Johnson Revenue Pfizer Revenue
Q4 2024 $22.5 billion (quarter ended Dec. 29, 2024) $17.8 billion (quarter ended Dec. 31, 2024)
Q1 2025 $21.9 billion (quarter ended March 30, 2025) $13.7 billion (quarter ended March 30, 2025)
Q2 2025 $23.7 billion (quarter ended June 29, 2025) $14.7 billion (quarter ended June 29, 2025)
Q3 2025 $24.0 billion (quarter ended Sept. 28, 2025) $16.7 billion (quarter ended Sept. 28, 2025)
Q4 2025 $24.6 billion (quarter ended Dec. 28, 2025) $17.6 billion (quarter ended Dec. 31, 2025)
Q1 2026 $24.1 billion (quarter ended March 29, 2026) $14.4 billion (quarter ended March 29, 2026)
Q2 2026 $25.3 billion (quarter ended June 28, 2026) $15.0 billion (quarter ended June 28, 2026)
Q3 2026 $25.4 billion (quarter ended Sept. 27, 2026) $16.6 billion (quarter ended Sept. 27, 2026)

Foolish Take

First off, don't be concerned about the drops in revenue you see in the chart for both companies as you read left to right. That reflects the seasonality of the businesses, which often can be traced back to doctors and patients loading up on prescriptions toward the end of a calendar year, when many patients have met their health insurance deductibles.

While ideally, a quarterly revenue chart would show rising bars from left to right, this seasonality means a better evaluation would be to compare each quarter to its prior-year quarter. For instance, JNJ's third quarter of 2026 saw positive gains over the third quarter of 2025. Yet Pfizer's sales actually show a slight dip in Q3 2026 compared to the same period in 2025. That's a red flag for investors to pay attention to.

We also do see less fluctuation from JNJ, in part because the business has 28 products and platforms that each generate more than $1 billion in annual sales. Pfizer, meanwhile, is trying to recover from a post-COVID-19 letdown, with fewer people getting the COVID vaccine each year as we get further from the pandemic.

Data source: Financial Modeling Prep. Data as of Nov. 17, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.